Nermin Kahraman

1.3k total citations
32 papers, 913 citations indexed

About

Nermin Kahraman is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Nermin Kahraman has authored 32 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 15 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Nermin Kahraman's work include MicroRNA in disease regulation (10 papers), Circular RNAs in diseases (7 papers) and Cancer-related molecular mechanisms research (7 papers). Nermin Kahraman is often cited by papers focused on MicroRNA in disease regulation (10 papers), Circular RNAs in diseases (7 papers) and Cancer-related molecular mechanisms research (7 papers). Nermin Kahraman collaborates with scholars based in United States, Türkiye and Egypt. Nermin Kahraman's co-authors include Bülent Özpolat, Recep Bayraktar, Gabriel Lopez‐Berestein, George A. Călin, Ahmed A. Ashour, Zühal Hamurcu, Pınar Kanlikilicer, Emine Bayraktar, Cristina Ivan and Hamada A. Mokhlis and has published in prestigious journals such as Cancer Research, Oncogene and Clinical Cancer Research.

In The Last Decade

Nermin Kahraman

30 papers receiving 911 citations

Peers

Nermin Kahraman
Lan Yang China
Fang Lou China
Nancy De Nève Belgium
Changye Zou China
Sima Orouei Iran
Fanni Li China
Sung Hee Hong South Korea
Meng-Ning Wei China
Lan Yang China
Nermin Kahraman
Citations per year, relative to Nermin Kahraman Nermin Kahraman (= 1×) peers Lan Yang

Countries citing papers authored by Nermin Kahraman

Since Specialization
Citations

This map shows the geographic impact of Nermin Kahraman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nermin Kahraman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nermin Kahraman more than expected).

Fields of papers citing papers by Nermin Kahraman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nermin Kahraman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nermin Kahraman. The network helps show where Nermin Kahraman may publish in the future.

Co-authorship network of co-authors of Nermin Kahraman

This figure shows the co-authorship network connecting the top 25 collaborators of Nermin Kahraman. A scholar is included among the top collaborators of Nermin Kahraman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nermin Kahraman. Nermin Kahraman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Karakaş, Didem, Ahmed A. Ashour, Hamada A. Mokhlis, et al.. (2025). eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progression via the tumor microenvironment. Cell Death and Disease. 16(1). 501–501.
3.
Kara, Göknur, et al.. (2024). Abstract 650: Pim3 kinase is a poor prognostic marker and novel molecular target for triple negative breast cancer. Cancer Research. 84(6_Supplement). 650–650. 1 indexed citations
4.
Pällmann, Nora, Ke Deng, Martina Tesikova, et al.. (2021). Stress-Mediated Reprogramming of Prostate Cancer One-Carbon Cycle Drives Disease Progression. Cancer Research. 81(15). 4066–4078. 18 indexed citations
5.
Önder, Ferah Cömert, Nermin Kahraman, Esen Bellur Atıcı, et al.. (2021). Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo. ACS Pharmacology & Translational Science. 4(2). 926–940. 13 indexed citations
6.
Önder, Ferah Cömert, Nermin Kahraman, Esen Bellur Atıcı, et al.. (2021). Correction to “Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo”. ACS Pharmacology & Translational Science. 4(3). 1247–1247. 2 indexed citations
7.
Görür, Ayşegül, Recep Bayraktar, Cristina Ivan, et al.. (2021). ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular Therapy — Nucleic Acids. 23. 930–943. 36 indexed citations
8.
Önder, Ferah Cömert, Serdar Durdağı, Nermin Kahraman, et al.. (2021). Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies. Bioorganic Chemistry. 116. 105296–105296. 7 indexed citations
9.
Pällmann, Nora, Martina Tesikova, Hatice Zeynep Nenseth, et al.. (2019). Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. Oncogene. 38(35). 6301–6318. 41 indexed citations
10.
11.
Bayraktar, Recep, Cristina Ivan, Emine Bayraktar, et al.. (2018). Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clinical Cancer Research. 24(17). 4225–4241. 74 indexed citations
12.
Bircan, Ahmet, Nilgün Gürbüz, Apar Pataer, et al.. (2018). Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer. 124. 31–39. 37 indexed citations
13.
Mokhlis, Hamada A., Recep Bayraktar, Nashwa Kabil, et al.. (2018). The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Molecular Therapy — Nucleic Acids. 14. 301–317. 28 indexed citations
14.
Kabil, Nashwa, Recep Bayraktar, Nermin Kahraman, et al.. (2018). Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Research and Treatment. 171(3). 593–605. 67 indexed citations
15.
Kanlikilicer, Pınar, Recep Bayraktar, Merve Denizli, et al.. (2018). Exosomal Mirna Confers Chemo Resistance Via Targeting Cav1/p-gp/M2-Type Macrophage Axis in Ovarian Cancer. SSRN Electronic Journal. 2 indexed citations
16.
Kanlikilicer, Pınar, Recep Bayraktar, Merve Denizli, et al.. (2018). Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 38. 100–112. 185 indexed citations
17.
Kahraman, Nermin, et al.. (2018). PO-289 Identification of microenvironmental regulation and therapeutic targeting of ongenic EF-2 kinase in pancreatic cancer. ESMO Open. 3. A340–A341. 1 indexed citations
18.
Şahin, Kazım, Cemal Orhan, Mehmet Tuzcu, et al.. (2017). Chemopreventive and Antitumor Efficacy of Curcumin in a Spontaneously Developing Hen Ovarian Cancer Model. Cancer Prevention Research. 11(1). 59–67. 26 indexed citations
19.
Shahbazi, Reza, et al.. (2017). Modified gold-based siRNA Nanotherapeutics for Targeted Therapy of triple-negative Breast Cancer. Nanomedicine. 12(16). 1961–1973. 37 indexed citations
20.
González-Villasana, Vianey, Enrique Fuentes‐Mattei, Cristina Ivan, et al.. (2015). Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research. 21(9). 2127–2137. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lan Yang Breakdown of academic impact, for papers by Fang Lou Breakdown of academic impact, for papers by Nancy De Nève Breakdown of academic impact, for papers by Changye Zou Breakdown of academic impact, for papers by Sima Orouei Breakdown of academic impact, for papers by Fanni Li Breakdown of academic impact, for papers by Sung Hee Hong Breakdown of academic impact, for papers by Meng-Ning Wei
Rankless by CCL
2026